Drug Profile
Ulotaront - Otsuka Pharmaceutical/Sumitomo Pharma/Sumitomo Pharma America
Alternative Names: SEP-363856; SEP-856Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer Sumitomo Pharma; Sumitomo Pharma America
- Class Amines; Antidepressants; Antipsychotics; Anxiolytics; Neuropsychotherapeutics; Pyrans; Sleep disorder therapies; Small molecules; Thiophenes
- Mechanism of Action 5-HT1A serotonin receptor agonists; Trace amine-associated receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Major depressive disorder; Schizophrenia
- Phase II/III Generalised anxiety disorder
- Phase II Psychotic disorders
- Preclinical Mental disorders
- No development reported Narcolepsy
Most Recent Events
- 15 Mar 2024 Sumitomo Pharma completes a phase I trial in Schizophrenia (In adults, Treatment-experienced) in USA (PO) (NCT05848700)
- 15 Mar 2024 Sumitomo Pharma terminates a phase II/III trial in Schizophrenia in China, Japan, Taiwan and Philippines due to the company business strategy (NCT04825860)
- 12 Feb 2024 Sunovion Pharmaceuticals completes a phase I trial for Schizophrenia in USA (PO) (NCT05542264)